Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.

Area of Science:

• Immunotherapy
• Cancer Biology
• Drug Delivery Systems

Background:

• Chimeric antigen receptor-T (CAR-T) cell therapy shows promise for hematologic cancers but struggles with solid tumors due to the immunosuppressive tumor microenvironment (TME).
• The TME in solid tumors often involves immune suppression and metabolic challenges that limit CAR-T cell function and persistence.

Purpose of the Study:

• To develop genetically programmable cellular vesicles (D@aPD-L1 NVs) to dismantle the immunosuppressive TME.
• To enhance the efficacy of anti-mesothelin CAR-T cells in treating orthotopic lung cancer by targeting the TME.

Main Methods:

• Engineered vesicles (D@aPD-L1 NVs) were developed, expressing anti-programmed death-ligand 1 (PD-L1) single chain variable fragment (scFv) and loaded with glutamine antagonists.
• These NVs were designed for targeted delivery to tumor sites, binding to PD-L1 on tumor cells.
• The effects of D@aPD-L1 NVs on immunosuppressive cells, inflammatory cells, and cytokines within the tumor tissue were evaluated.

Main Results:

• D@aPD-L1 NVs successfully delivered glutamine antagonists to the tumor site, addressing PD-L1 upregulation and preventing CAR-T cell exhaustion.
• These NVs significantly reduced immunosuppressive cells while promoting inflammatory cell recruitment and cytokine secretion in tumor tissues.
• The treatment improved CAR-T cell infiltration, effector functions, anti-tumor activity, and long-term memory immunity.

Conclusions:

• D@aPD-L1 NVs represent a promising strategy to enhance CAR-T cell therapy effectiveness against solid tumors.
• Metabolically dismantling the immunosuppressive TME with targeted vesicles can overcome key limitations of current CAR-T cell therapies.
• This approach holds potential for strengthening anti-tumor responses and establishing durable immunity in solid cancer treatment.